Wednesday, February 7, 2007
Article in the Los Angeles Times -- Study finds dangers in heart-surgery drug, by Denise Gellene:
Raising fresh concerns about a widely used heart-surgery medicine, a study released Tuesday reported that the drug Trasylol increased patients' long-term risk of dying by nearly 50%.
An estimated 10,000 deaths worldwide could be avoided over the next five years if Trasylol were not used, according to the report in the Journal of the American Medical Assn.
The study, funded by the San Bruno, Calif.-based Ischemia Research and Education Foundation, said Trasylol was unnecessary for most patients because safer and cheaper alternatives were available. The drug, also known by its generic name, aprotinin, is used to control bleeding during open-heart surgery.
Dr. Dennis T. Mangano of the foundation and lead author of the study said Trasylol should be restricted to patients with the highest risk of bleeding complications.